ライフサイエンスコーパス: desmopressin

1 mRNA, and cAMP production induced by dDAVP (desmopressin).

2 fter water restriction and administration of desmopressin.

3 onfirmed by treatment with the AC6 stimulant desmopressin.

4 binding assay, and no or partial response to desmopressin.

5 eibel-Palade body (WPB) secretagogues except desmopressin.

6 ical control in vivo, rats were treated with desmopressin.

7 c surgery can benefit from administration of desmopressin.

8 e treatment of patients unresponsive to this desmopressin.

9 03 target genes, but only in the presence of desmopressin.

10 cortisone, sex steroids, growth hormone, and desmopressin.

11 elective vasopressin type 2 receptor agonist desmopressin (1 nmol.kg(-1)) or continuous intravenous i

12 Desmopressin (1-deamino-8-d-arginine vasopressin [DDAVP]

13 to vehicle-infused animals (3 +/- 2%) in the desmopressin (40 +/- 6%, p < .001) and arginine vasopres

14 tay of therapy for most patients with vWD in desmopressin, a pharmacologic agent that stimulates the

15 oratory test accurately predicts response to desmopressin, a trial test should always be performed in

16 We administered desmopressin, a V2 receptor-specific agonist, to wild-ty

17 l regulation of ECV transfer and report that desmopressin, a vasopressin analogue, stimulated the upt

18 rats subjected to dehydration, treated with desmopressin acetate (dDAVP), or water loaded.

19 Patients were nearly unresponsive to desmopressin acetate, consistent with a lack of regulate

20 e first included two studies and showed that desmopressin administered to brain-dead patients was not

21 The cystogenic effect of desmopressin administration was markedly enhanced in Pkd

22 e suffered from marked polyuria resistant to desmopressin administration.

23 Desmopressin altered the translation rate rather than th

24 ty, with a preserved aquaporin-2 response to desmopressin and an intact response to furosemide.

25 Some patients will require treatment with desmopressin and it is important to avoid 'overshoot' ia

26 tment of bleeding in VWD involves the use of desmopressin and plasma-derived VWF concentrates and a v

27 Desmopressin can be useful only in a few type 2 cases co

28 e enough to require replacement therapy with desmopressin (DDAVP) and/or von Willebrand factor (VWF)/

29 The patient responded to large doses of desmopressin (dDAVP) which decreased urine volume from 1

30 10 to 50 micro M) potentiated the effects of desmopressin (DDAVP), prostaglandin E(2) (PGE(2)), and i

31 sence or presence of the vasopressin analog, desmopressin (dDAVP).

32 Desmopressin (DDAVP; 1-deamino-[d-Arg(8)]vasopressin) is

33 1-deamino-8-d-arginine vasopressin (desmopressin [DDAVP]) is clinically efficacious in patie

34 cells to the synthetic vasopressin analogue, desmopressin, did not affect exosomal flotillin-1 or TSG

35 After 5 d of drinking 5% dextrose, desmopressin does not increase the osmolality of the uri

36 sensitivity of renal tubules, a reduction in desmopressin dose might be necessary in patients with ce

37 nd out whether patients who can benefit from desmopressin during cardiac surgery can be identified by

38 e for treatment of uremic bleeding including desmopressin, erythropoietin, and estrogens.

39 ith the placebo group, patients who received desmopressin had less blood loss in 24 h (mean 624 [SD 2

40 entify the mechanism of action and safety of desmopressin in the clinical setting.

41 in; and combined infusion of selepressin and desmopressin increased fluid accumulation to levels simi

42 Interestingly, desmopressin increased the translation of seven glutathi

43 Desmopressin induced regulatory changes in SPAK variants

44 Because desmopressin is already deaminated at the N-terminal, it

45 Desmopressin may reduce inhibitor risk by avoiding expos

46 Furthermore, desmopressin modulated both the full-length and truncate

47 ardiopulmonary bypass were randomly assigned desmopressin (n=50) or placebo (n=51).

48 tients, particularly those not responding to desmopressin or requiring a sustained hemostatic correct

49 eating monosyptomatic enuresis refractory to desmopressin, prevalence of enuresis when screening larg

50 n a patient with central diabetes insipidus, desmopressin reduced the excretion of ECVs derived from

51 Seven of these patients had a robust desmopressin response and significantly reduced VWF half

52 However, predictors of desmopressin response have been recently identified, all

53 Administration of desmopressin resulted in only a modest effect on renal c

54 but the heterogenous biological response to desmopressin, showing large interindividual variation, m

55 racked exosomal AQP2 upregulation induced by desmopressin stimulation of kidney collecting duct cells

56 output and its role in patient selection for desmopressin therapy.

57 by exosomes was demonstrated: exosomes from desmopressin-treated cells stimulated both AQP2 expressi

58 in exosomal AQP2 concentration that followed desmopressin treatment of mice and a patient with centra

59 The main interventions described were desmopressin use, triiodothyronine and methylprednisolon

60 e care, clot ratios in patients who received desmopressin were similar to those in the untreated cont

61 he selective vasopressin V2 receptor agonist desmopressin were similarly investigated.